Crossfire Oncology

Executive Summary

Crossfire Oncology is a private, early-stage biotechnology company based in Utrecht, Netherlands, founded in 2021. The company focuses on developing innovative cancer therapies by targeting kinases through three complementary modalities: antibodies, biologics, and small molecules. Kinase dysregulation is a well-established driver of many cancers, and Crossfire's multi-pronged approach aims to address this critical pathway with precision. While the company has not disclosed specific pipeline candidates or clinical programs, its strategy aligns with proven therapeutic areas that have revolutionized cancer treatment. As a private entity with limited public information, Crossfire represents an early-stage opportunity with significant potential but also high risk, typical for preclinical biotech ventures. The company's ability to advance its programs towards clinical development and secure partnerships or funding will be key to its near-term trajectory.

Upcoming Catalysts (preview)

• TBDLead Program IND Filing30% success
• TBDPreclinical Data Presentation at Major Conference40% success
• TBDSeries A Financing or Strategic Partnership25% success